- by sedlv
- May 8 2023
Boehringer and Ginkgo Ink Potential $400M+ Metagenomics Deal for “Undruggable” Targets
(May 8, 2023) | By Inside Precision Medicine.

Ginkgo Bioworks today announced a new partnership with Boehringer Ingelheim to use Ginkgo’s metagenomic sequence database to find candidates to address undruggable targets. The two companies will leverage Ginkgo’s natural product discovery capabilities to “accelerate the discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs that are out of reach of conventional drug discovery.”